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<Abstract> 
BACKGROUND: One of the basic characteristics of cancer is heterogeneity. The 
heterogeneity of the tumor tissue is thought to influence its sensitivity to anticancer 
agents and/or radiation, and is thought one of the major causes of resistance to treatment. 
The purpose of this study was to assess whether the heterogeneity of the intratumoral 
glucose metabolism in esophageal squamous cell carcinoma (ESCC), as determined by 
a fractal dimension analysis of FDG-PET, can accurately predict the patient prognosis.  
METHODS: FDG-PET was performed in 125 consecutive patients with ESCC. We 
investigated the correlation between the fractal dimension (FD), as a parameter of the 
tumor heterogeneity calculated by a box-counting method, and the patient prognosis.  
RESULTS: The median FD was 1.97 (range, 1.7941 －2.0359). The survival curve was 
analyzed using the median FD as the cutoff value. The survival rate in the high-FD 
group was significantly better than that in the low-FD group as determined by the 
Kaplan-Meier method (P = 0.0029). In the multivariate survival analysis, the FD was 
identified as an independent prognostic factor for the overall survival (<0.0001). 
Furthermore, we analyzed the overall survival rate in the patients who were treated with 
surgery alone and with neoadjuvant chemotherapy. The Kaplan-Meier analysis of this 
data also showed that the high-FD group had a significantly better survival than did the 
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low-FD group (P = 0.0011, P = 0.0177). 
CONCLUSIONS: An FD analysis of the glucose metabolism in ESCC by FDG-PET 
may be useful to predict the prognosis.  
 
Key words: esophageal cancer, 18F-fluorodeoxyglucose (FDG), positron emission 
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<Introduction> 
Based on the results of the JCOG9907 trial, surgical treatment after chemotherapy 
using cisplatin and 5-fluorouracil (5-FU) has become the standard treatment for locally 
advanced esophageal squamous cell carcinoma (ESCC) in Japan [1]. However, the 
five-year survival rate is still low, and ESCC is considered to have a poor prognosis. 
Recently, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has 
been widely used for detecting lymph node and distant metastasis of esophageal cancer, 
as well as to diagnose recurrent disease. Furthermore, some researchers have suggested 
that FDG-PET may be able to predict the outcome of patients with esophageal cancer. 
For example, there was a report that the number of PET-positive lymph nodes was a 
prognostic factor predicting both the disease-free survival and overall survival [2]．On 
the other hand, the intensity of FDG uptake in adenocarcinoma did not demonstrate any 
significant relationship with the patient survival [3].  
The use of FDG-PET for such purposes is controversial, because there are problems 
such as false-positives due to inflammation and differences in the imaging conditions 
between facilities. The maximum standard uptake value (SUVmax) is widely used as a 
quantitative index reflecting the glucose metabolism in FDG-PET, but the uptake of 
FDG is not uniform in a tumor. This is because a malignant tumor is a complicated 
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tissue, with heterogeneous organization constructed by a variety of cells [4], and it is 
thought that the intratumoral glucose metabolism is therefore also heterogeneous.  
The objective of the present study was to assess the prognostic efficacy of 
quantifying the heterogeneity of the intratumoral glucose metabolism in FDG-PET by a 
fractal dimension analysis. 
 
<Materials and Methods> 
Patient population 
From January 2007 to December 2011, a total of 393 patients were enrolled in this 
study at our institution. All patients underwent upper gastrointestinal endoscopy and 
were histologically proven to have squamous cell carcinoma (SCC). The radiological 
diagnosis and UICC-TNM staging [5] were performed by computed tomography (CT), 
barium esophagography, magnetic resonance imaging (MRI) and FDG-PET.  
Clinical Stage 0 was diagnosed in 19 patients, IA in 63 patients, IB~IIIA (locally 
advanced resectable tumor, non-T4) was found in 125 patients and IIIC and IV 
disease (non-resectable tumor and distant metastasis) was found in 175 patients. After 
excluding the cStage 0, IA, IIIC and IV cases, 125 patients were investigated in this 
study. Finally, 79 patients were treated with surgical resection; 38 with surgery alone, 
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32 patients were treated with neoadjuvant chemotherapy and surgery and nine patients 
were treated with neoadjuvant chemoradiotherapy and surgery. The remaining 46 
patients did not receive surgery because of upstaging of the disease (N=5) or 
complications (cardiac dysfunction, N=2; cerebral infarction, N=5; chronic obstructive 
pulmonary disease (COPD), N=6;  liver dysfunction, N=2; another cancer, N=13; 
patient rejection, N=6; renal dysfunction, N=2; ECOG performance status of 4, N=4; 
adverse effect of NAC, N=1) (Fig. 1).   
 
Surgical treatment 
All patients received a transthoracic en bloc esophagectomy with termino-lateral 
anastomosis in the upper chest, including an abdominal lymphadenectomy, an extended 
en bloc mediastinal lymphadenectomy and a neck lymphadenectomy, i.e., the three-field 
lymphadenectomy. The esophagus was reconstructed using a posterior mediastinal 
gastric tube. 
 
Neoadjuvant chemotherapy (NAC) 
The NAC consisted of two cycles of cisplatin (80 mg/m
2
 on day 1) and 5-fluorouracil 
(5-FU; 800mg/m
2
 in a continuous infusion for five days). 
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Neoadjuvant chemoradiotherapy (NACRT) 
In our institute, if there were five or more lymph node metastases detected clinically, 
we performed NACRT. This consisted of two cycles of cisplatin (15 mg/m
2
 from days 2 
to 6) and 5-FU (500 mg/m
2
 from days 1 to 5), plus 20 fractions of radiation therapy 
concomitantly for a total of 40 Gray.  Radiation therapy was performed with a long 
T-shaped field (including the bilateral supraclavicular, mediastinal and upper abdominal 
regions). 
 
PET imaging 
Prior to the treatment, PET imaging was performed using a whole body PET scanner 
(Advance Nxi, GE). Images were obtained by the following sequence: emission, 4 min; 
transmission, 2 min; thickness, 4.25 mm; matrix, 128×128 and data reconstruction, 
OZEM method. The whole body imaging was initiated 60 minutes after the injection of 
the FDG tracer, 370 MBq (10 mCi). Patients had fasted for at least four hours before 
FDG-PET. All patients underwent pretreatment FDG-PET. Three experienced nuclear 
physicians qualitatively evaluated all PET images. The SUV was defined as the 
concentration of radioactivity in the tissue or lesion ([MBq]/mL×patient body weight 
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(g) / injected dose (MBq), and the SUVmax was defined as the maximum value in the 
tumor lesion.   
 
Fractal dimension analysis 
We used the fractal dimension as a parameter for the tumor heterogeneity. A fractal 
dimension analysis [6] is a new method used for quantitatively analyzing the 
heterogeneity, nonuniformity or complexity, and is used in a wide variety of domains, 
such as physics, earth science, meteorology, hydrodynamics, civil engineering, etc [7]. 
In the medical field, it has been used for evaluating the response to anticancer therapy 
[8] and for evaluating the tumor malignancy [9]. Fractal geometry, as first introduced by 
B. Manderbrot in 1982 [6], is characterized by the self-similarity with the non-integer 
dimension (Fractal Dimension; FD). The Koch curve and the Sierpinski triangle are 
representative fractal objects possessing a FD [6]. Mandelbrot paid attention to the 
self-similarity of complicated structures in the natural world, and expanded the 
definition of the Hausdorff dimension in the natural world, and he coined the terms 
fractal dimension and fractal. Fractal geometry had now become one of the techniques 
used to study complex systems. 
One of the ways to measure the fractal dimension is the box-counting method (Fig. 2). 
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To calculate the dimension of the figure for a fractal, this fractal can be imagined to be 
lying on an evenly-spaced grid, and then the number of boxes required to cover the grid 
can be counted. The box-counting dimension is calculated by determining how this 
number changes as the grid is made finer by applying a box-counting algorithm. 
Using this technique, suppose that N(d) is the number of boxes of side length d 
required to cover the set. The fractal dimension, FD, is defined as :  
 
FD = －  
𝑙𝑜𝑔𝑁(𝑑)
𝑙𝑜𝑔𝑑
 
The FDG-PET image in the coronal section of the largest aspect of the tumor was 
gray-scaled and set as the region of interest (ROI), and the FD was measured for the 
tumor by the box-counting method (Fig. 3). To monitor the changes, we used a fractal 
analyzing software system (Hiroyuki SASAKI, Ph.D. National Agriculture and Food 
Research Organization (NARO)). The fractal dimension analysis is an appropriate 
procedure to describe the heterogeneity of a tumor. As the FD increases, the image 
becomes more complex, indicating that the tumor is more heterogeneous [10-12]． 
 
Statistical analysis 
The relationships among the groups and the clinical parameters were determined using 
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the chi-square method and Fisher’s exact test. For the survival analysis, the study 
groups were divided into two subgroups, a low group and a high group, using the 
median FD and SUVmax as the cutoff values, respectively. The survival rates were 
calculated by using the product-limit method described by Kaplan-Meier. The 
significance of differences in survival was analyzed by the log-rank test. To identify 
independent prognostic factors, we performed the univariate and multivariate analyses 
of survival using a Cox’s proportional hazard model. P values < 0.05 were considered to 
be statistically significant. 
 
<Results> 
Patient characteristics 
The primary tumors were detected in all 125 pts by FDG-PET imaging. The median 
FD and SUVmax was 1.97 (range 1.7941 －2.0359) and 14 (range 2.54943－36.406), 
respectively. The characteristics of the 125 patients are shown in Table 2. The median 
FD and SUVmax were used as the cutoff values between the high and low groups, 
respectively, in the sub-group analyses. The median age was 70 years old. A comparison 
of each of the groups and the clinical characteristics revealed significant associations 
between the FD and the following factors (Table 1): age (P = 0.0055), clinical tumor 
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status (cT) (P <0.0001), tumor size (P <0.0001) and the CYFRA level (P= 0.0372). 
 
Overall survival 
The survival curves were analyzed using the cutoff values for the FD and SUVmax. 
Statistically significant differences were noted between patients with FD values higher 
and lower than the median value, however, no significant differences were noted 
between patients with SUVmax values higher and lower than the median (Fig. 4). 
The overall survival (OS) rates were calculated by the Kaplan-Meier method for each 
of the following factors: age, tumor size, cT, cN, cStage, tumor marker (SCC and 
CYFRA), SUVmax and FD. There were significant correlations between the survival 
and the tumor size, cT, CYFRA and FD. A multivariate analysis showed that the FD was 
the most independent factor for patient survival (<0.0001) (Table 2).  
Furthermore, in the surgical treatment group, we analyzed the OS in the patients who 
were treated with surgery alone and those treated with surgery and NAC using the 
median value as a cutoff in each subgroup. Statistically significant differences were 
noted between patients with FD values higher and lower than the median value, 
however, no significant difference was noted between patients with a SUVmax value 
higher and lower than the median in each of the subgroups (Figs. 5, 6). 
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<Discussion> 
One of the basic characteristics of cancer is heterogeneity [4]. Tumor heterogeneity 
makes it difficult to treat the cancer, because the different cells within the tumor respond 
differently to the treatment [13], and tumor heterogeneity represent a new target for 
improving the patient prognosis. 
 There are various aspects leading to tumor heterogeneity, for example, cell-to-cell 
interactions, the cancer microenvironment, the cytokine milieu, etc. A lot of research is 
currently being performed using molecular biological techniques, but there has been 
little research approaching tumor heterogeneity by analyzing clinical images. One study 
showed that the FD of tissue specimens reflects the tumor heterogeneity, and could be 
used as a prognostic factor for laryngeal carcinoma [14]. A fractal dimension analysis 
with dynamic FDG-PET was useful for predicting the grade and prognosis of soft tissue 
sarcomas [9]. The FD analysis is becoming a new approach for detecting and stratifying 
a tumor’s malignancy. For example, the textural features of the tumor’s metabolic 
distribution extracted from baseline FDG-PET images allowed for the stratification of 
esophageal carcinoma patients in the context of predicting their response to therapy [15]. 
This suggests that analyzing the tumor heterogeneity is useful for investigating the 
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malignancy of esophageal cancer. 
In this study, we analyzed the FDG-PET images, using the FD as a parameter of tumor 
heterogeneity, not the conventional SUVmax. The SUVmax is the maximum value of 
one point in the glucose metabolism of the tumor, which may not be uniform throughout 
the tumor. It is difficult to apply such a partial characteristic to the whole complicated 
cancer tissue, so an analysis using the SUVmax may not accurately reflect the 
characteristics of the tumor. The SUVmax in adenocarcinoma did not demonstrate any 
significant relation with the patient survival [3]. By evaluating the overall properties of 
the tumor, the FD can be used to evaluate the heterogeneity of the glucose metabolism 
in the tumor, in other words, individual cancer cells’ activity within the tumor. 
Based on the results of current study, the FD was extracted as an independent 
predictive factor in the univariate and multivariate analyses. In particular, the FD was 
the only prognostic biomarker predicting the overall survival in locally advanced ESCC 
patients in our study.  
The tumors with a high FD were considered to have high heterogeneity, while the 
tumors with a low FD were more uniform. The present findings were similar to previous 
studies indicating that tumors with high heterogeneity are associated with a poor 
prognosis. 
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There are many diagnostic imaging methods used for investigating the malignancy of 
ESCC, for example, the apparent diffusion coefficient values in diffusion-weighted 
imaging can predict the prognosis of patients with ESCC, as well as the response to 
treatment [16], and perfusion CT can predict the response to chemoradiation therapy 
and the survival in ESCC [17]. 
PET has a disadvantage in terms of the time required for data collection and in is 
spatial resolution, but has an advantage in that it can be used to evaluate the presence of 
distant metastases. Using an FD analysis allows for the simultaneous analysis of the 
prognosis along with the detection of metastases, because it can be analyzed using an 
image obtained during ordinary PET, so no additional imaging procedure is needed, 
minimizing the exposure to radiation and contrast agents. 
A limitation of the present study is that it was retrospective, and the patients with 
esophagitis, diabetes, claustrophobia, small tumors and prior chemoradiotherapy were 
not evaluated. Future studies will be needed in expanded populations to confirm our 
present findings. 
To our knowledge, this is the first study to evaluate the usefulness of FD for predicting 
the prognosis of patients with ESCC. 
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<Conclusion> 
A FD analysis of the glucose metabolism in ESCC by FDG-PET may be useful to 
predict the patient prognosis.  
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Parameter  No. of  
patients  
FD 
(median 1.97)  
 
 
SUVmax 
(median 14)  
  
 
High  Low   PFD  High  Low  PSUV  
 n = 125  n = 62  n = 63   n = 63  n = 62   
Age (years) 
≥70 /<70   65 / 60  40 / 22  25 / 38  0.0055 38 / 25 27 / 35 0.0606 
Gender 
male / female  113 / 12  58 / 4  55 / 8  0.3634 60 / 3 53 / 9 0.0756 
cT  
1 / 2 / 3  4 / 32 / 89  0 / 5 / 57  4 / 27 / 32  <0.0001  0 / 6 / 57  4 / 26 / 32 <0.0001  
Size (cm) 
> 5.0 / < 5.0 52 / 73  41 / 21  11 / 52  <0.0001  38 / 25 14 / 48 <0.0001  
CYFRA  
(ng/mL) 
> 2.0 / < 2.0 34 / 89  22 / 39  12 / 50  0.0372 21 / 41 13 / 48 0.1180 
SCC 
(ng/mL) 
> 1.5 / <1.5 49 / 73  28 / 33  21 / 40  0.1961 28 / 34 21 / 39 0.2524 
FD indicates fractal dimension; SUV, standardized uptake value. CFYRA and SCC are 
tumor markers for squamous cell carcinoma. 
 
Table 1. The patient characteristics and the cutoff values for the FD and SUVmax 
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Characteristics Univariate Multivariate 
 
HR 95%CI P HR 95%CI P 
Age(years) 
≥ 70 1.096 0.673-1.785 0.7123 
   
Size (cm) 
≥ 5 cm 1.653  1.013-2.698  0.0442  0.597  0.330-1.081  0.0888  
cT 3  2.481  1.362-4.521  0.0030  1.316  0.640-2.708  0.4555  
cN(+)  1.264  0.774-2.062  0.3488 
   
cStage Ⅲ  1.216  0.725-2.039  0.4577  
   
SCC(ng/mL) 
≥ 1.5  1.414 0.849-2.354 0.1829 
   
CYFRA (ng/mL) 
≥ 2.0  2.030 1.187-3.472 0.0097 2.004 1.143-3.513 0.0152 
SUV 
≥ 14  1.585 0.970-2.589 0.0660  
   
FD 
≥ 1.97  4.330  2.555-7.337  <0.0001  4.756  2.462-9.188  <0.0001  
HR, Hazard ratio; CI, Confidence interval 
Table 2: Prognostic factors in the 125 patients with ESCC 
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Figure 1. The patient population. We investigated 125 patients with locally advanced 
resectable tumors excluding cT4 (cStage IB~IIIA) tumors, which are shown surrounded 
by a dotted line.  
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Figure 2. The box-counting method. To calculate the dimension of the figure for a 
fractal, imagine that this figure lying on an evenly-spaced grid, and count how many 
boxes are required to cover the figure. Suppose that N(d) is the number of boxes of side 
length d required to cover the set, for example, N(d) is 14 for a and 27 for b. This 
number changes as we make the grid finer. The fractal dimension is calculated as the 
absolute value of the slope of the regression line on the log-log plot of the relationship 
between d and N(d). 
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Figure 3. Representative images. a. A coronal image of a patient with esophageal 
squamous cell carcinoma (arrow). b. A whole body FDG-PET image which is 
gray-scaled. We set the region of interest (ROI) as a square for the tumor, and measured 
the FD by the box-counting method. 
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Figure 4. The overall survival rates of the 125 patients. The survival rates according to 
the median FD (a) and SUVmax (b) are shown. The Kaplan-Meier survival rates and p 
values were calculated according to the log-rank test. The median FD and SUVmax 
values were used as the cutoff values for the high and low groups, respectively. 
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Figure 5. The overall survival rates of the surgery alone group (38 patients). The 
survival rates according to the median FD (a) and SUVmax (b) are shown. The 
Kaplan-Meier survival rates and p values were calculated according to the log-rank test. 
The median FD and SUVmax values in the 38 patients were used as the cutoff values 
for the high and low groups, respectively. 
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Figure 6. The overall survival rates of the NAC group (32 patients). The survival rates 
according to the median FD (a) and SUVmax (b) are shown. The Kaplan-Meier survival 
rates and p values were calculated according to the log-rank test. The median FD and 
SUVmax values in the 32 patients were used as the cutoff values for the high and low 
groups, respectively. 
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